1
|
Caputo SM, Telly D, Briaux A, Sesen J, Ceppi M, Bonnet F, Bourdon V, Coulet F, Castera L, Delnatte C, Hardouin A, Mazoyer S, Schultz I, Sevenet N, Uhrhammer N, Bonnet C, Tilkin-Mariamé AF, Houdayer C, Moncoutier V, Andrieu C, French COVAR Group Collaborators, Bièche I, Stern MH, Stoppa-Lyonnet D, Lidereau R, Toulas C, Rouleau E. 5' Region Large Genomic Rearrangements in the BRCA1 Gene in French Families: Identification of a Tandem Triplication and Nine Distinct Deletions with Five Recurrent Breakpoints. Cancers (Basel) 2021; 13:cancers13133171. [PMID: 34202044 PMCID: PMC8268747 DOI: 10.3390/cancers13133171] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/30/2021] [Revised: 06/11/2021] [Accepted: 06/17/2021] [Indexed: 12/28/2022] Open
Abstract
Simple Summary Large genomic rearrangements in BRCA1 consisting of deletions/duplications of one or several exons are complex events, often occurring in the 5′ region. We characterized 10 events in 20 families: one large triplication classified as benign and nine large deletions classified as pathogenic. The breakpoint localization will certainly help to further understand the chromatin structure in regions sensitive to rearrangement. Abstract Background: Large genomic rearrangements (LGR) in BRCA1 consisting of deletions/duplications of one or several exons have been found throughout the gene with a large proportion occurring in the 5′ region from the promoter to exon 2. The aim of this study was to better characterize those LGR in French high-risk breast/ovarian cancer families. Methods: DNA from 20 families with one apparent duplication and nine deletions was analyzed with a dedicated comparative genomic hybridization (CGH) array, high-resolution BRCA1 Genomic Morse Codes analysis and Sanger sequencing. Results: The apparent duplication was in fact a tandem triplication of exons 1 and 2 and part of intron 2 of BRCA1, fully characterized here for the first time. We calculated a causality score with the multifactorial model from data obtained from six families, classifying this variant as benign. Among the nine deletions detected in this region, eight have never been identified. The breakpoints fell in six recurrent regions and could confirm some specific conformation of the chromatin. Conclusions: Taken together, our results firmly establish that the BRCA1 5′ region is a frequent site of different LGRs and highlight the importance of the segmental duplication and Alu sequences, particularly the very high homologous region, in the mechanism of a recombination event. This also confirmed that those events are not systematically deleterious.
Collapse
Affiliation(s)
- Sandrine M. Caputo
- Department of Genetics, Institut Curie, F-75248 Paris, France; (S.M.C.); (A.B.); (V.M.); (C.A.); (I.B.); (M.-H.S.); (D.S.-L.); (R.L.)
- Institut Curie, PSL Research University, F-75005 Paris, France
| | - Dominique Telly
- Laboratoire d’Oncogénétique, Institut Claudius Regaud, IUCT-O, F-31059 Toulouse, France;
| | - Adrien Briaux
- Department of Genetics, Institut Curie, F-75248 Paris, France; (S.M.C.); (A.B.); (V.M.); (C.A.); (I.B.); (M.-H.S.); (D.S.-L.); (R.L.)
- Institut Curie, PSL Research University, F-75005 Paris, France
| | - Julie Sesen
- Department of Neurosurgery, Boston Children’s Hospital, Boston, MA 02115, USA;
| | - Maurizio Ceppi
- Roche Innovation Center Basel (RICB), Roche Pharma Research and Early Development, CH-4052 Basel, Switzerland;
| | - Françoise Bonnet
- Laboratoire de Génétique Constitutionnelle et INSERM U916 VINCO, Institut Bergonié, CEDEX, F-33076 Bordeaux, France; (F.B.); (N.S.)
| | - Violaine Bourdon
- Laboratoire d’Oncogénétique Moléculaire, Département de Biologie du Cancer, Institut Paoli-Calmettes, F-13273 Marseille, France;
| | - Florence Coulet
- Department of Genetics, Pitié-Salpêtriere Hospital, Assistance Publique-Hopitaux de Paris, Sorbonne University, F-75013 Paris, France;
| | - Laurent Castera
- Laboratoire de Biologie et de Génétique du Cancer, CLCC François Baclesse, INSERM 1079 Centre Normand de Génomique et de Médecine Personnalisée, F-14076 Caen, France; (L.C.); (A.H.)
| | - Capucine Delnatte
- Service de Génétique Médicale, Unité de Génétique Moléculaire, CHU Nantes, F-44093 Nantes, France;
| | - Agnès Hardouin
- Laboratoire de Biologie et de Génétique du Cancer, CLCC François Baclesse, INSERM 1079 Centre Normand de Génomique et de Médecine Personnalisée, F-14076 Caen, France; (L.C.); (A.H.)
| | - Sylvie Mazoyer
- Centre de Recherche en Neurosciences de Lyon, INSERM, U1028, CNRS, UMR5292, Université de Lyon, F-69008 Lyon, France;
| | - Inès Schultz
- Centre Paul Strauss, Laboratoire de Biologie Tumorale—Oncogénétique, F-67000 Strasbourg, France;
| | - Nicolas Sevenet
- Laboratoire de Génétique Constitutionnelle et INSERM U916 VINCO, Institut Bergonié, CEDEX, F-33076 Bordeaux, France; (F.B.); (N.S.)
| | - Nancy Uhrhammer
- Biologie Clinique et Oncologique, Biologie Moléculaire—Centre Jean Perrin, F-63000 Clermont-Ferrand, France;
| | - Céline Bonnet
- Institut de Cancérologie, 6 Avenue de Bourgogne, F-54519 Vandœuvre-lès-Nancy, France;
| | - Anne-Françoise Tilkin-Mariamé
- Cancer Research Center of Toulouse (CRCT), Institut National de la Santé et de la Recherche Médicale (INSERM) UMR 1037, F-31000 Toulouse, France;
| | - Claude Houdayer
- Inserm U1245, UNIROUEN, Normandie University, Normandy Centre for Genomic and Personalized Medicine, F-76183 Rouen, France;
- Normandy Centre for Genomic and 41 Personalized Medicine, Department of Genetics, University Hospital, F-76183 Rouen, France
| | - Virginie Moncoutier
- Department of Genetics, Institut Curie, F-75248 Paris, France; (S.M.C.); (A.B.); (V.M.); (C.A.); (I.B.); (M.-H.S.); (D.S.-L.); (R.L.)
- Institut Curie, PSL Research University, F-75005 Paris, France
| | - Catherine Andrieu
- Department of Genetics, Institut Curie, F-75248 Paris, France; (S.M.C.); (A.B.); (V.M.); (C.A.); (I.B.); (M.-H.S.); (D.S.-L.); (R.L.)
- Institut Curie, PSL Research University, F-75005 Paris, France
| | | | - Ivan Bièche
- Department of Genetics, Institut Curie, F-75248 Paris, France; (S.M.C.); (A.B.); (V.M.); (C.A.); (I.B.); (M.-H.S.); (D.S.-L.); (R.L.)
- Faculty of Pharmaceutical and Biological Sciences, University of Paris, F-75006 Paris, France
| | - Marc-Henri Stern
- Department of Genetics, Institut Curie, F-75248 Paris, France; (S.M.C.); (A.B.); (V.M.); (C.A.); (I.B.); (M.-H.S.); (D.S.-L.); (R.L.)
- Institut Curie, INSERM U830, DNA Repair and Uveal Melanoma (D.R.U.M.), PSL Research University, F-75005 Paris, France
| | - Dominique Stoppa-Lyonnet
- Department of Genetics, Institut Curie, F-75248 Paris, France; (S.M.C.); (A.B.); (V.M.); (C.A.); (I.B.); (M.-H.S.); (D.S.-L.); (R.L.)
- Institut Curie, INSERM U830, DNA Repair and Uveal Melanoma (D.R.U.M.), PSL Research University, F-75005 Paris, France
- Faculty of Medicine, University of Paris, F-75005 Paris, France
| | - Rosette Lidereau
- Department of Genetics, Institut Curie, F-75248 Paris, France; (S.M.C.); (A.B.); (V.M.); (C.A.); (I.B.); (M.-H.S.); (D.S.-L.); (R.L.)
- Institut Curie, PSL Research University, F-75005 Paris, France
| | - Christine Toulas
- Laboratoire d’Oncogénétique, Institut Claudius Regaud, IUCT-O, F-31059 Toulouse, France;
- Correspondence: (C.T.); (E.R.)
| | - Etienne Rouleau
- Department of Biology, Gustave Roussy, Université Paris-Saclay, F-94805 Villejuif, France
- Correspondence: (C.T.); (E.R.)
| |
Collapse
|
2
|
Laurent S, Gehrig C, Nouspikel T, Amr SS, Oza A, Murphy E, Vannier A, Béna FS, Carminho-Rodrigues MT, Blouin JL, Cao Van H, Abramowicz M, Paoloni-Giacobino A, Guipponi M. Molecular characterization of pathogenic OTOA gene conversions in hearing loss patients. Hum Mutat 2021; 42:373-377. [PMID: 33492714 DOI: 10.1002/humu.24167] [Citation(s) in RCA: 14] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/16/2020] [Revised: 12/02/2020] [Accepted: 12/16/2020] [Indexed: 11/11/2022]
Abstract
Bi-allelic loss-of-function variants of OTOA are a well-known cause of moderate-to-severe hearing loss. Whereas non-allelic homologous recombination-mediated deletions of the gene are well known, gene conversions to pseudogene OTOAP1 have been reported in the literature but never fully described nor their pathogenicity assessed. Here, we report two unrelated patients with moderate hearing-loss, who were compound heterozygotes for a converted allele and a deletion of OTOA. The conversions were initially detected through sequencing depths anomalies at the OTOA locus after exome sequencing, then confirmed with long range polymerase chain reactions. Both conversions lead to loss-of-function by introducing a premature stop codon in exon 22 (p.Glu787*). Using genomic alignments and long read nanopore sequencing, we found that the two probands carry stretches of converted DNA of widely different lengths (at least 9 kbp and around 900 bp, respectively).
Collapse
Affiliation(s)
- Sacha Laurent
- Department of Diagnostic, Genetic Medicine Unit, University Hospitals of Geneva, Geneva, Switzerland
| | - Corinne Gehrig
- Department of Diagnostic, Genetic Medicine Unit, University Hospitals of Geneva, Geneva, Switzerland
| | - Thierry Nouspikel
- Department of Diagnostic, Genetic Medicine Unit, University Hospitals of Geneva, Geneva, Switzerland
| | - Sami S Amr
- Laboratory for Molecular Medicine, Mass General Brigham Personalized Medicine, Cambridge, Massachusetts, USA
| | - Andrea Oza
- Laboratory for Molecular Medicine, Mass General Brigham Personalized Medicine, Cambridge, Massachusetts, USA
| | - Elissa Murphy
- Laboratory for Molecular Medicine, Mass General Brigham Personalized Medicine, Cambridge, Massachusetts, USA
| | - Anne Vannier
- Department of Diagnostic, Genetic Medicine Unit, University Hospitals of Geneva, Geneva, Switzerland
| | - Frédérique Sloan Béna
- Department of Diagnostic, Genetic Medicine Unit, University Hospitals of Geneva, Geneva, Switzerland.,Department of Genetic Medicine and Development, University of Geneva Medical School, Geneva, Switzerland
| | | | - Jean-Louis Blouin
- Department of Diagnostic, Genetic Medicine Unit, University Hospitals of Geneva, Geneva, Switzerland.,Department of Genetic Medicine and Development, University of Geneva Medical School, Geneva, Switzerland
| | - Hélène Cao Van
- Department of Otorhinolaryngology, Head and Neck Surgery, Pediatric Otolaryngology Unit, University Hospitals of Geneva, Geneva, Switzerland
| | - Marc Abramowicz
- Department of Diagnostic, Genetic Medicine Unit, University Hospitals of Geneva, Geneva, Switzerland.,Department of Genetic Medicine and Development, University of Geneva Medical School, Geneva, Switzerland
| | - Ariane Paoloni-Giacobino
- Department of Diagnostic, Genetic Medicine Unit, University Hospitals of Geneva, Geneva, Switzerland.,Department of Genetic Medicine and Development, University of Geneva Medical School, Geneva, Switzerland
| | - Michel Guipponi
- Department of Diagnostic, Genetic Medicine Unit, University Hospitals of Geneva, Geneva, Switzerland.,Department of Genetic Medicine and Development, University of Geneva Medical School, Geneva, Switzerland
| |
Collapse
|
3
|
Kong S, Li L, Zhu W, Xin L, Ruan J, Zhang Y, Yang S, Li K. Genetic characteristics of polycistronic system‑mediated randomly‑inserted multi‑transgenes in miniature pigs and mice. Mol Med Rep 2017; 17:37-50. [PMID: 29115474 PMCID: PMC5780143 DOI: 10.3892/mmr.2017.7842] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/13/2016] [Accepted: 06/28/2017] [Indexed: 11/24/2022] Open
Abstract
Multi-transgenic technology is superior to single transgenic technology in biological and medical research. Multi-transgene insertion mediated by a polycistronic system is more effective for the integration of polygenes. The multi-transgene insertion patterns and manners of inheritance are not completely understood. Copy number quantification is one available approach for addressing this issue. The present study determined copy numbers in two multi-transgenic mice (K3 and L3) and two multi-transgenic miniature pigs (Z2 and Z3) using absolute quantitative polymerase chain reaction analysis. For the F0 generation, a given transgene was able to exhibit different copy number integration capacities in different individuals. For the F1 generation, the most notable characteristic was that the copy number proportions were different among pedigrees (P<0.05). The results of the present study demonstrated that transgenes within the same vector exhibited the same integration trend between the F0 and F1 generations. In conclusion, intraspecific consistency and intergenerational copy numbers were compared and the integration capacity of each specific transgene differed in multi-transgenic animals. In particular, the copy number of one transgene may not be used to represent other transgenes in polycistronic vector-mediated multi-transgenic organisms. Consequently, in multi-transgenic experimental animal disease model research or breeding, copy numbers provide an important reference. Therefore, each transgene in multi-transgenic animals must be separately screened to prevent large copy number differences, and inconsistent expression between transgenes and miscellaneous data, in subsequent research.
Collapse
Affiliation(s)
- Siyuan Kong
- State Key Laboratory of Animal Nutrition, Key Laboratory of Farm Animal Genetic Resource and Germplasm Innovation of Ministry of Agriculture, Institute of Animal Sciences, Chinese Academy of Agricultural Sciences, Beijing 100193, P.R. China
| | - Li Li
- State Key Laboratory of Animal Nutrition, Key Laboratory of Farm Animal Genetic Resource and Germplasm Innovation of Ministry of Agriculture, Institute of Animal Sciences, Chinese Academy of Agricultural Sciences, Beijing 100193, P.R. China
| | - Wenjuan Zhu
- State Key Laboratory of Animal Nutrition, Key Laboratory of Farm Animal Genetic Resource and Germplasm Innovation of Ministry of Agriculture, Institute of Animal Sciences, Chinese Academy of Agricultural Sciences, Beijing 100193, P.R. China
| | - Leilei Xin
- State Key Laboratory of Animal Nutrition, Key Laboratory of Farm Animal Genetic Resource and Germplasm Innovation of Ministry of Agriculture, Institute of Animal Sciences, Chinese Academy of Agricultural Sciences, Beijing 100193, P.R. China
| | - Jinxue Ruan
- State Key Laboratory of Animal Nutrition, Key Laboratory of Farm Animal Genetic Resource and Germplasm Innovation of Ministry of Agriculture, Institute of Animal Sciences, Chinese Academy of Agricultural Sciences, Beijing 100193, P.R. China
| | - Yubo Zhang
- Animal Functional Genomics Group, Agricultural Genomes Institute at Shenzhen, Chinese Academy of Agricultural Sciences, Shenzhen, Guangdong 518120, P.R. China
| | - Shulin Yang
- State Key Laboratory of Animal Nutrition, Key Laboratory of Farm Animal Genetic Resource and Germplasm Innovation of Ministry of Agriculture, Institute of Animal Sciences, Chinese Academy of Agricultural Sciences, Beijing 100193, P.R. China
| | - Kui Li
- State Key Laboratory of Animal Nutrition, Key Laboratory of Farm Animal Genetic Resource and Germplasm Innovation of Ministry of Agriculture, Institute of Animal Sciences, Chinese Academy of Agricultural Sciences, Beijing 100193, P.R. China
| |
Collapse
|